Skip to main content

Table 2 Prices of several hormonal agents for prostate cancer in Australia (as of January 2016)

From: Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy

Hormonal agent/s Form and strength Price ($AUD) Reference
Full price PBS (maximum number of repeats for PBS price)
Advanced or high-risk hormone naïve prostate cancer (clinical tumor stages T3–T4, PSA > 20 ng/mL)
Goserelin acetate 3.6 mg implant $323.50 $38.30 (5) [114]
10.8 g implant $1101.16 $38.30 (1) [114]
Triptorelin acetate 3.75 mg injection $413.75 $38.30 (5) [115]
22.5 mg injection $2123.34 $38.30 (0) [115]
Goserelin acetate and Bicalutamide 3.6 mg implant and 50 mg tablet (28 tablets), respectively $472.81 $38.30 (5) [116]
10.8 mg implant and 50 mg tablet (28 tablets), respectively $1240.02 $38.30 (0) [116]
Leuprorelin (or leuprolide) acetate 30 mg injection $1442.09 $38.30 (1) [117]
Degarelix 80 mg injection $413.75 $38.30 (5) [118]
120 mg injection $432.92 $38.30 (0) [118]
Bicalutamide 50 mg tablet (28 tablets) $98.40 $38.30 (5) [119]
Flutamide 250 mg tablets (100 tablets) $169.70 $38.30 (5) [120]
Nilutamide 150 mg tablet (30 tablets) $223.68 $38.30 (5) [121]
Metastatic castration-resistant prostate cancer (mCRPC) (histologically confirmed prostate cancer, N1/M1, more than two [or three in other studies] consecutive rises in PSA levels over 25 % above nadir value following surgical or chemical ADT for at least 1 week)
Abiraterone acetate 250 mg tablet (120 tablets) $3600.41 $38.30 (2) [122]
Enzalutamide 40 mg capsule (112 capsules) $3700.17 $38.30 (2) [123]
  1. PBS pharmaceutical benefits scheme